Understanding triglycerides. When the value counts and what moves it

What are triglycerides and what does the value in a blood panel say?

Triglycerides are fats that transport fatty acids in your blood and sit in fat tissue as an energy store. Part of them comes from food, part your body makes itself. The laboratory value describes how much of them is currently in transit. Together with the cholesterol values it belongs, according to the European guideline on dyslipidaemias, to the lipid profile with which the risk of cardiovascular disease is estimated.

Triglycerides do not float freely in the blood but travel in transport particles. After eating these are mainly chylomicrons from the intestine, in between mainly VLDL from the liver, meaning the triglyceride-rich particles your liver builds itself. That is exactly why the triglyceride value is not a still image but a snapshot of your fat metabolism.

A single value says little on its own. The European guideline does not estimate cardiovascular risk from a single blood fat but from age, sex, smoking status, blood pressure and the other blood fats, plus pre-existing conditions such as diabetes or reduced kidney function. Only in this context does a triglyceride value give a picture.

What also matters is what actually does harm. The triglycerides themselves are mainly a marker. According to the European consensus statement of 2021, what is causally involved in vascular risk are the transport particles and their breakdown products, so-called remnant cholesterol. It does not follow, however, that every lowering of the triglyceride value lowers the risk of heart attack.

Which triglyceride values count as normal and when are they too high?

Below 150 mg/dl the value counts as desirable, which corresponds to 1.7 mmol/l. The European guideline on dyslipidaemias, supplemented in 2025 by a focused update, states that values below 1.7 mmol/l point to a lower risk and that higher values are a reason to look for further risk factors. The European consensus statement on lipid measurement names the same boundary as the desirable value and has laboratories flag everything from 1.7 mmol/l, meaning from 150 mg/dl, as abnormal. The professional societies do not derive a separate treatment target for triglycerides from this; LDL cholesterol remains decisive for that. The European societies only draw the boundary to the severe form at around 880 mg/dl, meaning at 10 mmol/l.

The US guideline of several professional societies, published in 2026, grades more finely. It names a moderate elevation from 150 to 499 mg/dl, a severe one from 500 to 999 mg/dl and a very severe one from 1000 mg/dl. The table below shows both classifications with exactly the values that appear in the guidelines.

What matters is the scale upwards. A value of around 600 mg/dl is not a stronger variant of 250 mg/dl but a different question. Under the current US classification it lies in the severe range and belongs in prompt medical assessment, because there the risk of pancreatitis counts and no longer the long-term vascular risk alone.

One classification you still find in many guides is out of date. It comes from a guideline of an endocrinology society from 2012, which only set the severe form from 1000 mg/dl. That guideline was withdrawn in October 2025. If a text still describes 600 mg/dl as moderate, the classification comes from there.

For Germany there is no freely available reference sample that reports triglycerides in percentiles by age and sex. The values in the table are therefore classification boundaries from professional societies and not the distribution of a German population sample. On top of that, reference ranges can differ between laboratories because different test methods are in use.

Do you have to be fasting for a triglyceride measurement?

For the first assessment, no. A joint consensus statement of the European Atherosclerosis Society and the European laboratory medicine federation from 2016 recommends determining blood fats routinely without fasting. The basis is population studies with over 300,000 non-fasting people and three large statin trials with 43,000 participants in total. In German practices and laboratories, fasting collection with a food break of about 8 hours nevertheless remains usual. There is no German guideline that contradicts the European recommendation. A specialist review from 2026 describes exactly this gap, because measurement without fasting is recommended internationally but has not yet arrived in practice in many countries. For a planned fasting collection the food break remains a sensible preparation; a precondition of every measurement it is not.

The difference is smaller than the fasting rule suggests. In an analysis of routine laboratory data from 209,180 people, triglycerides after a habitual meal were on average at most 26 mg/dl higher, so around 21 percent. In a Danish population study with 33,391 people the difference was just as large; in a study of women with 26,330 participants it was 18 mg/dl, so around 16 percent. The reason is simple: a habitual meal raises the value far less than a fat tolerance test.

It is different when raised triglycerides are already known. Then a fasting measurement should be taken, as the US guideline of 2026 states. If a value measured without fasting is above 5 mmol/l, meaning above 440 mg/dl, a fasting control measurement may be considered according to the European consensus statement. Fasting measurement also remains sensible where an inherited disorder of fat metabolism is suspected, during ongoing care at a lipid clinic, after pancreatitis caused by high triglycerides, when starting medicines that raise the value considerably, and when a fasting blood glucose or another value requiring fasting is being determined anyway. The treatment thresholds of the guidelines also refer to values measured while fasting.

In practice this means two things. If your value is just above 150 mg/dl and you ate two hours beforehand, do not compare it with a fasting value from last year. And on the day of the test it can make sense to avoid particularly fatty meals, for instance a burger with fries and a milkshake. The consensus statement advises this as a conditional pointer, not as a requirement.

From what triglyceride value does it become dangerous for the pancreas?

It becomes critical far above the values that stand out in everyday life, but that is not a safety boundary, because the European guideline states in the same place that pancreatitis can also occur between 440 and 880 mg/dl, meaning between 5 and 10 mmol/l. The European consensus statement of 2016 lists triglycerides above 10 mmol/l, meaning above around 880 mg/dl, as a life-threatening concentration with a high risk of acute pancreatitis. As a cause of such inflammation, the value counts according to the German pancreatitis guideline usually from 1000 mg/dl. Where serum is visibly milky, this is in part assumed from about 10 mmol/l onwards.

The risk does not begin only there. In a Danish population study with 116,550 participants, a good six years of observation and 434 cases of disease, the risk at non-fasting values of 2.0 to 2.9 mmol/l was a good twice as high as at values below 1.0 mmol/l, and from 5.0 mmol/l almost ninefold. The ninefold figure is only a mean with considerable imprecision, because few cases occurred in this group and the data allow a considerably smaller as well as a considerably larger multiple. In absolute terms it stays small. In the group from 1.0 to 1.9 mmol/l there were 4.3 cases per 10,000 person-years, at 2.0 to 2.9 mmol/l 5.5 and from 5.0 mmol/l 12. The comparison in each case was with values below 1.0 mmol/l. It is notable that the relative risks in this study rose more steeply for the pancreas than for heart attack.

How often high triglycerides lie behind acute pancreatitis depends on region and patient group. After gallstones and alcohol they are the third most common cause. A systematic review from 2025 with 110 studies and over three million participants arrives at 11.6 percent worldwide, at 5.4 percent in Western countries and at 16.3 percent in Eastern countries. For Germany the Western order of magnitude is the fitting one. The German guideline names about 10 percent of cases; a further systematic review from 2025 arrives across 77 studies at around 20 percent with a range from 1.6 to 47.6 percent. The figures therefore diverge widely depending on region and the group examined; younger people, men and people with repeated episodes are affected above average.

The practical message is unambiguous. At values of this magnitude the consensus statement provides for laboratories to flag the result specially and for those affected to be referred immediately to a lipid clinic or to a medical practice specialising in fat metabolism. Sudden, very severe pain in the upper abdomen, often radiating in a belt shape into the back and accompanied by nausea, vomiting or fever, can be a sign of acute pancreatitis. Such symptoms belong in immediate assessment, outside practice hours in the emergency department, because the condition is treated in hospital and can become life-threatening in a severe course. The pain is not unambiguous. It can also radiate into the chest and flanks, and the same set of symptoms can be a heart attack. That is exactly why it belongs in medical assessment and not in self-assessment. Everything below that you discuss calmly with a doctor rather than treating yourself.

Anyone who has been through pancreatitis caused by high triglycerides has a clear target afterwards. The international guideline of 2025 recommends keeping triglycerides permanently below 500 mg/dl in order to prevent a relapse. For the first two days there is fasting, after which a low-fat diet follows.

What lies behind very high values?

From 880 mg/dl, meaning from 10 mmol/l, one speaks of chylomicronaemia, meaning a quantity of blood fat at which the transport particles become visible in the blood. In the vast majority of cases it arises from the interplay of several factors, namely an inherited predisposition plus alcohol, diabetes, excess weight or triggering medicines. The foundational review on the classification of high triglycerides states explicitly that in adults the great majority have this multifactorial form. The value can then often be lowered considerably when these factors are treated.

Very rarely there is a congenital form, familial chylomicronaemia syndrome. A consensus paper from 2025 puts it at 1 to 10 cases per million people, while the multifactorial form affects about 1 in 500. In it, the function of an enzyme of fat breakdown is missing. This form usually begins early in life, barely responds to the usual medicines and requires a very strict, permanently low-fat diet as well as specialised care. Here a genetic test can make sense. The difference matters in practice, because lifestyle and correcting triggers work in the common form and barely in the congenital one.

Why pregnancy is a special case

In pregnancy triglycerides rise strongly and naturally, according to a review from 2026 by two to fourfold, peaking in the final third. Usually this is unproblematic. Anyone who already had raised values beforehand, however, should have them checked early, ideally in the first third of pregnancy. In rare cases pancreatitis occurs, which is dangerous for mother and child. Higher values are also associated with pre-eclampsia and pregnancy-induced hypertension. Treatment options are limited in pregnancy, which is why early planning with the care team is decisive.

Why can your triglycerides be high and your LDL normal?

Because triglyceride-rich particles carry their own carrier protein. In the lipoprotein overview of the European guideline, chylomicrons carry ApoB-48 while VLDL and IDL carry ApoB-100, meaning the same carrier protein as LDL. An unremarkable LDL can therefore sit alongside many triglyceride-rich particles. That is precisely why the European guideline recommends determining ApoB as a measure of particle number particularly where triglycerides are high, in diabetes, in obesity and at very low LDL. The US guideline of 2026 goes a step further and, at triglycerides from 150 mg/dl, places non-HDL cholesterol or ApoB ahead of LDL for decision-making, because the calculated LDL underestimates the actual risk where triglycerides are high.

There is also a calculation problem. LDL is often not measured in the laboratory but calculated from total cholesterol, HDL and triglycerides. The classic route estimates the share of the triglyceride-rich particles as triglycerides in mg/dl divided by 5. From 400 mg/dl this route is no longer usable, and from about 177 mg/dl it already underestimates the LDL. Modern laboratories therefore calculate with more precise formulas. The US guideline of 2026 describes these calculation methods as preferred, and explicitly also over direct LDL measurement, because the available direct methods are not sufficiently standardised and not sufficiently validated and additionally cause costs. Excluded from this is the elaborate reference method, which is practically never used in routine work.

The calculation routes have limits too. They are well established above all for triglyceride values below about 400 mg/dl. Above that, up to about 800 mg/dl, there are variants developed specifically for the purpose that at least deliver usable estimates; the higher the triglycerides, however, the more uncertain the LDL value becomes. If triglycerides are higher still, LDL cholesterol can no longer be given reliably, and then other values from the same laboratory test are more meaningful, for instance non-HDL cholesterol or ApoB.

From the same figures, remnant cholesterol can be derived, meaning total cholesterol minus LDL minus HDL. As long as LDL is calculated classically, it corresponds exactly to the triglycerides divided by 5 in mg/dl. With the more precise formulas or with direct measurement, this shortcut no longer holds. The European consensus statement describes calculated remnant cholesterol as a strong causal risk factor. It is nevertheless not measured routinely, because the guidelines use non-HDL cholesterol or ApoB for that, which are available from the normal lipid profile.

What drives your triglycerides up?

At the start there is usually a shared pattern. Raised triglycerides, excess weight around the abdomen, a raised blood sugar and a fatty liver have a common root, namely insulin resistance. That is why they usually occur together and also improve together. Fatty liver has been called MASLD since 2023, meaning metabolic dysfunction-associated steatotic liver disease. The earlier term non-alcoholic fatty liver is out of date, because it only described what the condition is not. Anyone with raised triglycerides should therefore also keep an eye on blood sugar and liver values, and vice versa.

Common triggers are alcohol, poorly controlled diabetes, marked excess weight and a sugar-rich diet. With alcohol, the liver releases more triglyceride-rich particles. The effect is dose-dependent, differs considerably between individuals and is more pronounced where a disorder of fat metabolism already exists. An underactive thyroid or a kidney disease can also lie behind it; both can be clarified with a blood test. An inherited predisposition also plays a part, though purely single-gene forms are rare.

With medicines a closer look is worthwhile, because the magnitudes lie far apart. A consensus statement on secondary disorders of fat metabolism from 2024 puts the strongest effect at ritonavir, an older medicine against HIV, with a rise in triglycerides of 200 to 300 percent. According to the same data, oral contraceptives with second and third generation progestogens raise the value by up to 50 to 75 percent, and oral oestrogens without a progestogen dose-dependently by 30 to 40 percent. Oestrogen via patch or gel, by contrast, barely acts on triglycerides, because it does not pass through the liver first. Also named are cortisone, tamoxifen, some medicines for mental illness, particularly olanzapine and clozapine, as well as medicines after an organ transplant. Beta blockers and diuretics tend to raise the values slightly. Do not therefore stop any medicine on your own initiative. Whether there is an alternative, for instance switching from a tablet to a patch, belongs in the consultation.

That is the big difference from lipoprotein(a). Lipoprotein(a) is essentially genetically determined and barely movable through lifestyle. Triglycerides react to alcohol, sugar, exercise and weight; they are the most movable part of your lipid profile.

What lowers triglycerides and what does not?

A companion review to the European guideline quantifies how strongly individual lifestyle changes act on triglycerides. With alcohol the reaction varies greatly. Where starting values are high and consumption heavy, reductions of up to 80 percent have been described in studies; with moderate consumption the effect lies in the range of a few mg/dl. Weight loss acts more evenly, in intervention studies at around 8 mg/dl per kilogram. According to the same data, endurance training lowers the value by about 10 to 20 percent and omega-3 fatty acids from food by about 10 to 15 percent. Added to that are fewer carbohydrates overall and fewer simple and double sugars. Setting these figures against one another achieves little, because they come from different studies with different starting positions, and the measures act on different causes. Moderate alcohol consumption of up to about 10 grams a day counts as acceptable to the guideline as long as triglycerides are not raised. For exercise it names no particular form of training.

The US guideline of 2026 grades its recommendations by the level of the value. At 150 to 499 mg/dl the guideline names little added sugar, meaning below 6 percent of calories, few refined carbohydrates, as little alcohol as possible, plus 5 to 10 percent weight loss and at least 150 minutes of exercise per week. According to the same guideline, at 500 to 999 mg/dl abstaining from alcohol is added and fat intake is limited to 20 to 25 percent, above 1000 mg/dl to 10 to 15 percent.

A raised triglyceride value indicates a raised risk. Unlike lowering LDL cholesterol, however, lowering triglycerides has so far not achieved a lower risk of heart attack. One large trial in over 10,000 people with type 2 diabetes lowered triglycerides by around 26 percent without reducing the number of cardiovascular events. For LDL lowering, by contrast, the benefit is well established, which is why LDL cholesterol remains the most important treatment target where cardiovascular risk is raised. Lowering very high triglycerides serves above all to reduce the risk of pancreatitis.

What medicines and supplements can do and what they cannot

Omega-3 fatty acids lower triglycerides, but the preparation and the dose are decisive. The European professional societies state explicitly in their 2025 update that food supplements and vitamins are not recommended for lowering cardiovascular risk. Only one high-dose, prescription-only preparation is named there, and only in addition to a statin in people at high cardiovascular risk with raised fasting triglycerides. A comparable trial with a different omega-3 combination at the same dose showed no benefit. High omega-3 doses can also promote atrial fibrillation, and this signal grows stronger with rising dose in analyses of several large trials. In Germany the preparation named is currently not available. Fish as a food, for instance two portions a week, remains a sensible part of a heart-healthy diet. A dosing recommendation belongs in the consultation and not in a blog article.

Very high triglycerides, in current guidelines from about 500 mg/dl and with clearly rising risk from 1000 mg/dl, count as an independent risk for acute pancreatitis. In this range a change of diet and lifestyle is often not enough. Whether and with what additional drug treatment is given is decided individually by the treating doctor, because the guidelines leave room here and assess the evidence differently. One endocrinology society even holds explicitly that the evidence for drug treatment from 500 mg/dl is insufficient. Very high values belong in specialised care in every case.

Between 150 and 1000 mg/dl too, drug treatment can be a topic, namely when your overall risk for heart and vessels is high. The European guideline provides for this possibility from 200 mg/dl. That is decided medically on the basis of your overall risk and not on the triglyceride value alone.

How do you convert triglycerides from mg/dl to mmol/l?

With triglycerides this is unambiguous. The European consensus statement of 2016 converts mmol/l into mg/dl by multiplying by 88. More precise is the factor 88.5, which follows from the molar mass of the reference fat. For everyday use the coarser factor is enough, so 1.7 mmol/l corresponds to around 150 mg/dl, 10 mmol/l to around 880 mg/dl and 11.3 mmol/l to around 1000 mg/dl.

That is not a given. With lipoprotein(a) the conversion between mg/dl and nmol/l is not cleanly possible, because the particles differ in size. With triglycerides, by contrast, you are measuring a defined quantity of substance, which is why a fixed factor works.

What most guides leave out about triglycerides

Three points are missing from most German overviews. First the gap on fasting, because European professional societies have held it not to be routinely necessary since 2016, while in Germany fasting collection remains usual. That is habit; there is no German guideline to the contrary. Second the scale upwards, because almost all guides treat 200 mg/dl and 1000 mg/dl as the same category of “too high”, although medically those are two different questions. And third, that the value alone decides almost nothing.

On the reality of German care: people with statutory insurance are entitled from the age of 35 to a general health examination every three years. The laboratory programme there covers a complete lipid profile of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Between 18 and 34 the entitlement exists once, but the blood tests there are tied to a risk profile, for instance a family history, obesity or high blood pressure. Without such indications the check-up at this age contains no lipid profile and therefore no triglyceride measurement. Anyone in their twenties without a risk profile who wants to see values regularly usually pays for them themselves. The German primary care guideline on cardiovascular risk counselling from 2025 explicitly rates repeated lipid measurements in people without risk factors as of little use.

And on placing it in the panel: if your triglycerides are raised, the more interesting question is not the triglyceride value itself but what it reveals about particle number, blood sugar and liver. That is why it never stands alone in a result with us.